US pharma major Merck & Co is trying to make its looming Keytruda (pembrolizumab) patent hill look more like a speed bump.
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
GlobalData on MSN
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff
MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback